{"id":42935,"date":"2025-10-09T15:13:25","date_gmt":"2025-10-09T07:13:25","guid":{"rendered":"https:\/\/flcube.com\/?p=42935"},"modified":"2025-10-09T15:13:26","modified_gmt":"2025-10-09T07:13:26","slug":"northeast-pharma-secures-nmpa-approval-for-dcty0801-injection-targeting-egfrviii%e2%80%91positive-brain-gliomas","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=42935","title":{"rendered":"Northeast\u202fPharma Secures NMPA Approval for DCTY0801\u202fInjection Targeting EGFRvIII\u2011Positive Brain Gliomas"},"content":{"rendered":"\n

China\u2011based Northeast Pharmaceutical Group Co., Ltd. (SHE: 000597<\/a>) has announced that its chimeric antigen receptor T\u2011cell therapy, DCTY0801 Injection, has received clearance from the National Medical Products Administration (NMPA) to initiate clinical trials for patients with recurrent or progressive high\u2011grade brain gliomas expressing the EGFRvIII mutant antigen.<\/p>\n\n\n\n

Targeted CAR\u2011T Platform<\/strong>
DCTY0801\u202fInjection is engineered to recognize the EGFRvIII mutation, a tumor\u2011specific antigen absent from normal tissues. Approximately 30\u202f% of glioblastoma cases harbor this mutation, yet therapeutic options targeting EGFRvIII in brain gliomas remain scarce. By delivering a CAR\u2011T construct that homes in on EGFRvIII, Northeast\u202fPharma aims to provide a novel treatment avenue for this aggressive malignancy.<\/p>\n\n\n\n

Regulatory Milestones and Future Outlook<\/strong>
The NMPA\u2019s approval to conduct trials marks a significant regulatory milestone, building on the product\u2019s earlier Orphan Drug Designation by the U.S. Food and Drug Administration in May\u202f2023. With trial initiation underway, the company anticipates generating pivotal clinical data that could accelerate the path to broader therapeutic access for patients with EGFRvIII\u2011positive gliomas.<\/p>\n\n\n\n

Key Takeaways<\/strong><\/p>\n\n\n\n